KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Finished Goods (2016 - 2022)

TherapeuticsMD filings provide 11 years of Finished Goods readings, the most recent being $4.5 million for Q3 2022.

  • On a quarterly basis, Finished Goods rose 42.36% to $4.5 million in Q3 2022 year-over-year; TTM through Sep 2022 was $4.5 million, a 42.36% increase, with the full-year FY2021 number at $2.9 million, down 12.3% from a year prior.
  • Finished Goods hit $4.5 million in Q3 2022 for TherapeuticsMD, up from $4.0 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $5.0 million in Q3 2019 to a low of $1.6 million in Q1 2018.
  • Median Finished Goods over the past 5 years was $3.3 million (2019), compared with a mean of $3.4 million.
  • Biggest five-year swings in Finished Goods: soared 122.24% in 2019 and later crashed 41.45% in 2021.
  • TherapeuticsMD's Finished Goods stood at $2.9 million in 2018, then soared by 71.09% to $5.0 million in 2019, then plummeted by 32.69% to $3.4 million in 2020, then decreased by 12.3% to $2.9 million in 2021, then skyrocketed by 54.42% to $4.5 million in 2022.
  • The last three reported values for Finished Goods were $4.5 million (Q3 2022), $4.0 million (Q2 2022), and $3.3 million (Q1 2022) per Business Quant data.